Associate ProfessorLiesel FitzGerald

Principal Research Fellow

Menzies Institute for Medical Research

  • Principal Research Fellow
    Menzies Institute for Medical Research
  • 6226 4263 (Work)
  • Menzies Institute for Medical Research, Menzies Institute for Medical Research, 439b Menzies MS2, Hobart CBD Campuses, TAS

RESEARCH SUMMARy

Research Themes

Assoc Prof FitzGerald’s research aligns with the University’s Better Health research theme. Her research aims to take advantage of the existing Tasmanian familial and case-control prostate cancer resources, consisting of both germline and tumour samples, to identify rare variants associated with risk of disease. This work will lead to better knowledge of the underlying biology involved in prostate cancer development and could identify biomarkers for disease screening as well as genomic targets for novel and existing therapies. This research uses a variety of methodologies including linkage analysis, whole genome sequencing, TaqMan genotyping and gene and protein expression detection techniques.

More recently, Assoc Prof FitzGerald has initiated a Tasmanian clinical and genomics resource, Biomarkers to Improve Outcomes in Prostate Cancer (BIOPC). This resource combines the clinically rich Prostate Cancer Outcomes Registry – Tasmania (PCOR-TAS) with germline and tumour samples from participating prostate cancer cases. Recently there have been major advances in understanding the genomics of prostate cancer risk but there are still significant gaps in understanding why a third of patients’ disease progresses to an aggressive form despite therapeutic intervention, and why some patients respond better than others to particular treatments. The proposed resource will allow us to address these issues, in addition to identifing disparities in diagnosis, treatment and outcomes (clinical and quality-of-life) across Tasmanian prostate cancer patients.

In the era of ‘precision medicine’, through their research Assoc Prof FitzGerald and her colleagues aim to move diagnosis and treatment of patients from a ‘one treatment suits all’ basis to an individual genomics-based approach. Essential components for the delivery of such a system include biospecimens that have been well characterised with clinical, treatment and outcomes data. Through the realisation of Assoc Prof FitzGerald’s research using unique Tasmanian prostate cancer resources, the way men are diagnosed and treated for prostate cancer, as well as disease outcomes, will be significantly improved.

Collaboration

Assoc Prof FitzGerald is participating in several national and international collaborative studies. A key research study that is currently underway with national collaborators, Professors Graham Giles (Cancer Council Victoria) and Melissa Southey (Monash University), aims to identify prognostic biomarkers using diagnostic prostate cancer tissue. Methodologies used in this research study include epigenome-wide methylation and transcriptome-wide gene expression assays. Assoc Prof FitzGerald also has long-standing and on-going research projects with international collaborator, Professor Janet Stanford (Fred Hutchinson Cancer Research Center). Currently, they have two studies underway including a next-generation whole exome sequencing study of prostate cancer families and a prognostic biomarker study that has applied transcriptome-wide gene expression arrays to radical prostatectomy tissue samples.

Awards

Cancer Council Tasmania/College of Health and Medicine Senior Research Fellowship 2018 – 2021
Open to Talent Research Fellowship 2015 – 2018
Cure Cancer/Movember Young Investigator Award 2013 - 2014
David Hill Cancer Council Victoria Fellowship 2012 – 2015
SPORE Post-Doctoral Fellowship 2007 – 2009
ASMR Medical Research Week Finalist 2007
Jeanne Foster Scholarship for professional development in cancer control 2005
Menzies Research Institute PhD Scholarship 2003 – 2006
Queensland Institute of Medical Research Honours Scholarship 1995

FUNDED PROJECTS

  • GRANT
    Uncovering new genetic and epigenetic drivers of brain cancer
    1 Jul 2026 - 30 Jun 2027
    People funded by this grant:
    • Marshall O,
    • Harrup R,
    • Dickinson J,
    • FitzGerald L
    Project Total: $143,999; The most common and aggressive form of adult brain cancer, glioblastoma, has devastating outcomes, and treatments have not improved significantly in decades. This leaves patients and their families with few effective options. Our project is trying to solve two fundamental problems: we do not fully understand what causes these tumours to form, and we lack effective drugs that can stop their growth. Our research tackles this by asking two key questions. First, why do some families have a higher rate of brain cancer? By studying Tasmanian families with a history of brain cancer, we aim to find specific inherited genes that increase a person's risk. Identifying these genes helps us uncover new causes of brain cancer, and could lead to better screening for families. Second, what cellular processes help cells become cancerous and grow uncontrollably? We are investigating the on/off switches that control genes inside the cancer cells. We have already found one of these master switches, a protein complex called SWI/SNF, that appears to be critical for tumour growth. To test our discoveries, we use fast-acting animal models of disease that allow us to see if a human gene variant causes cancer-like growth, or if a drug can stop it, in just a few weeks. This work directly addresses the urgent need for new therapies. By finding the underlying causes of brain cancer, we can identify individuals at higher risk, uncover new targets for drug development, and test potential new treatments more quickly, bringing much-needed hope to the brain cancer community. Funded by: Walter and Eliza Hall Institute of Medical Research - BCC Program 2025 Funding ($143,999); University of Tasmania.
  • GRANT
    Characterising Rare Prostate Cancer Risk Variants using a Prostate Organoid Model
    Cancer Council of Tasmania1 Mar 2026 - 28 Feb 2027
    People funded by this grant:
    • FitzGerald L,
    • Raspin K,
    • Smalley E,
    • Dickinson J
    Project Total: $30,000; Prostate organoids provide significant potential to investigate the function of genetic mutations in a model that closely mimics the normal human prostate. However, given the recent development of the prostate organoid methodology, this has not yet been explored. Earlier this year, we received funding from Tuxedo Junction (via Cancer Council Tasmania) to establish the prostate organoid methodology in our laboratory. This work is currently ongoing in collaboration with the Murdoch Childrens Research Institute (see Preliminary Data section below) and will result in a model that mimics the normal prostate environment. Here, we request funding to introduce a prostate cancer risk mutation into the iPSCs, so we can determine its functional impact on normal prostate cells and how it leads to prostate cancer development. Funded by: Cancer Council of Tasmania - Grant - Small Grant Program ($30,000); University of Tasmania.
  • GRANT
    Uncovering the genetic drivers of brain cancer in Tasmanians
    1 Jan 2026 - 30 Jun 2027
    People funded by this grant:
    • Marshall O,
    • Harrup R,
    • Dickinson J,
    • Thani N,
    • FitzGerald L
    Project Total: $99,955; Glioblastoma (GBM) remains the most lethal primary brain tumour in Tasmania, with limited therapeutic options and a pressing need for locally relevant research. This proposal builds on the Tasmanian Central Nervous System (CNS) Cancers Biobank established by CIs Harrup and Dickinson, and the unique cohort of extended Tasmanian families with inherited brain cancer, to provide an integrated, 18-month programme that links clinical genetics, high-throughput sequencing, and rapid Drosophila functional assays. The clinical team at Royal Hobart Hospital (RHH) will identify families with multiple cases of brain cancer and to obtain fresh-frozen tumour and blood samples through the Biobank. This effort will be led by CIHarrup (medical oncologist) and supported by CIGupta (consultant), CIRagg (registrar), and CIThani (neurosurgeon). Whole-genome sequencing of these families, performed by the Menzies Cancer Genetics group under CIDickinson, will uncover rare, high-risk variants that are under-represented in national datasets. Candidate genes will be prioritised on the basis of segregation, predicted impact, and relevance to known GBM pathways. Concurrently, the Menzies Neuroepigenetics group led by CIMarshall will generate humanised transgenic Drosophila that express the patient-derived variants in an established IDH-wildtype GBM model. Using inducible genetic systems, we will assess each variants effect on neural proliferation, tumour-like overgrowth, and epigenetic reprogramming. A parallel effort will create a novel IDH-mutant (R132H) GBM model, enabling direct comparison of variant function across the two major molecular subtypes of GBM. The fly assays are rapid, fully quantitative, reproducible, and amenable to medium-throughput drug screening, allowing us to test candidate therapeutics for blood-brain barrier penetration and tumour suppression. The grant will also support a postdoctoral researcher, Jake Newland, to drive the Drosophila functional work and integrate the findings with clinical data. The project will deliver three tangible outcomes for Tasmanian health: (1) a curated catalogue of rare, familial GBM variants linked to clinical phenotypes; (2) validated Drosophila models that provide rapid functional insight and a platform for pre-clinical drug testing; and (3) a translational pipeline that ulitmately will inform precision-medicine strategies for patients treated at RHH. By integrating local clinical expertise with cutting-edge genetics and in vivo functional genomics, the programme directly addresses the Foundations priorities of improving cancer outcomes, strengthening RHH research capacity, and fostering interdisciplinary collaboration across senior and junior investigators. Funded by: Royal Hobart Hospital Research Foundation - Research Project Grant ($99,955); University of Tasmania.
  • GRANT
    Understanding the Genetics of Prostate Cancer to Improve Diagnosis and Treatment Strategies
    1 Jan 2026 - 31 Dec 2026
    People funded by this grant:
    • FitzGerald L
    Project Total: $250,000; This research project will result in the identification of rare genetic variants that can predict prostate cancer risk and prognosis. These genetic variants will then be functionally characterised using our Tasmanian prostate cancer tissue resources and a novel prostate organoid model to provide the knowledge required to advance therapeutic options for patients. Funded by: Donation via Menzies Institute for Medical Research - Donation ($250,000); University of Tasmania.
  • GRANT
    Evaluating respondent burden for the EQ-HWB and EQ-HWB-S in prostate cancer
    1 Aug 2025 - 31 Jul 2027
    People funded by this grant:
    • Roydhouse J,
    • Finch A,
    • FitzGerald L,
    • Breslin M,
    • Norman R
    Project Total: $133,779; This study aims to examine respondent burden in prostate cancer. Funded by: EuroQol Foundation - Grant ($114,355); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Preventing Disease Progression in Prostate Cancer
    1 Aug 2025 - 31 Dec 2026
    People funded by this grant:
    • FitzGerald L,
    • Sweeney C
    Project Total: $203,825; Movember Preventing Disease Progression Program Funding will be used to complete the preparation and genetic analysis (SNP array assays) of approximately 700 germline patient samples from a Tasmanian population-based, case-only cohort from the Biomarkers to Improve Outcomes in Prostate Cancer (BIOPC) study. The goal of BIOPC is to create a powerful clinical and genetic resource to identify biomarkers associated with treatment outcomes and treatment-related side effects. BIOPC leverages the Movember funded Prostate Cancer Outcomes Registry (PCOR-TAS), aiming to collect germline and tumour samples for the majority of registry participants, which will be matched to PCOR-TASs extensive demographic, clinical, treatment and outcomes data. There are currently almost 1,100 BIOPC participants with germline DNA samples, with collection ongoing. To date, 384 samples have had genetic data (SNP array assays) generated, with another 700 assays proposed here, providing clinical-genomic data for approximately 1,100 BIOPC participants. Of these participants, two-thirds were diagnosed with clinically indolent/moderate disease, while a third were diagnosed with clinically significant prostate cancer. The newly generated genetic data will be cleaned up, harmonised with existing data, then integrated into the MSTIR Database at the Adelaide University. This work will be done in collaboration with Professor Chris Sweeney and the MSTIR Team at SAiGENCI/Adelaide University. Funded by: Movember Foundation ($203,825); University of Tasmania.
  • GRANT
    Implementing Patient-Reported Outcome Collection in Routine Prostate Cancer Care in Rural and Regional Settings
    31 Mar 2025 - 29 Feb 2028
    People funded by this grant:
    • Roydhouse J,
    • Van Dam P,
    • Jose K,
    • Zhao T,
    • FitzGerald L
    Project Total: $300,000; The overall goal of this proposal is to improve patient-centred prostate cancer care by implementing sustainable, achievable routine PRO data collection under the auspices of a clinical quality registry using an integrated knowledge translation approach. Funded by: Movember Foundation - Grant-PCOR-ANZ Research Grant ($300,000); University of Tasmania.
  • GRANT
    The Absolute Q digital PCR system from Applied Biosystems to help improve clinical pathways and outcomes for all Tasmanians
    1 Jul 2024 - 30 Jun 2025
    People funded by this grant:
    • Raspin K,
    • FitzGerald L
    Project Total: $40,000; As the only medical research institute in regional Tasmania, the Menzies Institute for Medical Research, University of Tasmania, houses the majority of the cutting-edge research equipment in the state. However, we are currently using one type of methodology that lacks sensitivity and requires large quantities of samples, which precludes it from being used with precious finite samples. This significantly hampers our ability to generate novel and cutting-edge data. Here, we are requesting funding to assist in the purchase of the Absolute Q digital PCR (dPCR) system from Applied Biosystems. The AQ dPCR will allow researchers to build and accelerate discovery and translational research capacity aligned to cancer, eye disease, brain science, genomics, preventative health and chronic disease, thus improving the health outcomes of Tasmania. The technology provided by the AQ dPCR will advance our research scope, which in turn will have a positive impact on the lives of Tasmanians by addressing diseases of significant public health concern. Funded by: Perpetual Trustees - Grant-Trust Fund ($40,000); University of Tasmania ($97,380).
  • GRANT
    Discovery of Rare Prostate Cancer Risk Variants to Innovate Gene-Based Clinical Tests
    1 Mar 2024 - 31 Aug 2026
    People funded by this grant:
    • FitzGerald L,
    • Dickinson J,
    • Raspin K
    Project Total: $99,894; We propose to identify and characterise novel, rare PrCa variants by applying whole genome sequencing to our powerful collection of large Tasmanian PrCa families. Funded by: Tour de Cure - Grant - Senior Research ($99,894); University of Tasmania.
  • GRANT
    Bringing Precision in Prostate Cancer Medicine to Tasmania
    1 Jan 2024 - 31 Dec 2025
    People funded by this grant:
    • Raspin K,
    • Roydhouse J,
    • Dickinson J,
    • FitzGerald L,
    • Nott L
    Project Total: $30,000; In Australia, precision medicine is delivering significant improvements in outcomes for several common cancers, yet such innovation for prostate cancer lags significantly behind, particularly in regional areas like Tasmania. As the prostate cancer clinical space embraces this innovation, it is imperative that we seek engagement from the Tasmanian community in the design of our clinical pathways for effective delivery of genetic information. This project will engage with Tasmanian men diagnosed with prostate cancer, their carers/family members and healthcare providers to identify important and acceptable patient reported outcome measure(s) related to genetic testing, which will allow us to develop tools to aide with the delivery of genetic information in the clinical management of prostate cancer. Funded by: Cancer Council of Tasmania - Grant-Small ($30,000); University of Tasmania ($1,953).
  • GRANT
    Identifying key drivers of metastatic bone lesions from several cancer types.
    1 Jun 2023 - 30 Jun 2024
    People funded by this grant:
    • Raspin K,
    • Dickinson J,
    • FitzGerald L,
    • Nott L
    Project Total: $13,900; Once cancers have spread, they become difficult to treat and increasingly resistant to therapy. Consequently, survival rates plummet, particularly for those with bone metastases. In this proposal, we aim to identify key changes between primary tumours and metastatic bone tumours in patients who have gone on to develop secondary cancer. This will allow us to identify the underlying reasons as to why some patients develop secondary cancers and others do not. Funded by: Cancer Council of Tasmania - Grant-Small ($13,900); University of Tasmania.
  • GRANT
    A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania
    1 Jan 2023 - 30 Jun 2024
    People funded by this grant:
    • FitzGerald L,
    • Dickinson J,
    • Skala M,
    • Donovan S,
    • Harris H
    Project Total: $24,943; We propose to continue growing our clinical and biospecimens prostate cancer resource. This project aims to collect biological samples from Tasmanian men participating in the Prostate Cancer Outcomes Registry, Tasmania. This valuable clinical and genomic resource will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,943); University of Tasmania ($31,396).
  • GRANT
    Closing the Health Gap: Precision Care for Men with Prostate Cancer (PC4PC-TAS)
    Royal Hobart Hospital Research Foundation1 Jan 2023 - 31 Dec 2027
    People funded by this grant:
    • Raspin K,
    • Dickinson J,
    • Roydhouse J,
    • Wallis M,
    • Lucas S
    Project Total: $448,222; In Australia, precision medicine is delivering significant improvements in outcomes for several common cancers, yet such innovation for prostate cancer (PrCa) lags significantly behind, particularly in regional areas like Tasmania. This study will undertake the consumer-focused work necessary to design and deliver patient-centred genomic medicine in PrCa. This will ensure we are able predict men at risk of developing aggressive PrCa and identify those men eligible for gene-based therapies. Funded by: Royal Hobart Hospital Research Foundation - Grant-Major Project ($448,223); Donation via University of Tasmania Foundation ($28,000); University of Tasmania.
  • GRANT
    Donation - Prostate cancer research
    28 Feb 2022 - 28 Feb 2026
    People funded by this grant:
    • FitzGerald L
    Project Total: $103,641; Donation from the Gerald Harvey Bequest fund in support of Liesel Fitzgerald's prostate cancer research Funded by: Donation via University of Tasmania Foundation - Donation ($103,651); University of Tasmania.
  • GRANT
    Precision Medicine for Men with Prostate Cancer
    1 Jan 2022 - 31 Mar 2024
    People funded by this grant:
    • Dickinson J,
    • Roydhouse J,
    • Raspin K,
    • FitzGerald L,
    • Harrup R
    Project Total: $21,142; Precision medicine and the burgeoning use of complex genetic data to inform clinical management of cancer is here. As Tasmania embraces this innovation, it is imperative that we seek engagement from the Tasmanian community in the design of our clinical pathways for delivery. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($21,142); University of Tasmania.
  • GRANT
    Understanding TMPRSS2:ERG gene fusions to improve prostate cancer diagnosis and treatment options
    1 Jan 2022 - 31 Dec 2023
    People funded by this grant:
    • FitzGerald L,
    • Dickinson J,
    • Raspin K
    Project Total: $24,776; This project aims to understand the impact the TMPRSS2:ERG fusion has on prostate cancer in the Tasmanian population. To do this we will determine the frequency of this fusion in our population and determine its association with clinicopathological features of prostate cancer. Funded by: Cancer Council of Tasmania - Grant-Small ($24,776); University of Tasmania.
  • GRANT
    Enhancing PCOR-ANZ using Data Linkage: A Pathfinder Pilot
    14 Jul 2021 - 4 Apr 2024
    People funded by this grant:
    • Roder D,
    • Buckley E,
    • Beckman K,
    • Moretti K,
    • FitzGerald L
    Project Total: $485,950; This project aims to demonstrate how data linkage can serve to enhance the capacity of the Prostate Cancer Outcomes Registry (PCOR) ANZ registry, addressing important research questions that will inform and improve the management of Australian men who are diagnosed with prostate cancer. Funded by: Movember Foundation - Grant-PCOR-ANZ Research Grant; University of South Australia; University of Tasmania.
  • GRANT
    Advancing Precision Medicine for Men Diagnosed with Prostate Cancer
    1 Jul 2021 - 30 Jun 2022
    People funded by this grant:
    • Raspin K,
    • Dickinson J,
    • FitzGerald L,
    • Marthick J
    Project Total: $10,470; Genetic study to identify key mutations underpinning aggressive PrCa. Funded by: Perpetual Trustees - CF - Betty Lowe Memorial ($10,470); University of Tasmania ($6,938).
  • GRANT
    Applying innovative 'omics' technologies to identify key molecular drivers of metastatic bone tumours
    1 Jul 2021 - 30 Jun 2022
    People funded by this grant:
    • Raspin K,
    • Dickinson J,
    • FitzGerald L,
    • Holloway A
    Project Total: $14,778; Once cancers have spread, they become difficult to treat and increasingly resistant to therapy. Consequently, survival rates plummet, particularly for those with bone metastases. Using cutting-edge technologies, we have identified key changes in genes that allow metastatic tumour cells to survive in bone. We aim to characterise the metastatic capabilities of these key changes and determine their value as prognostic/therapeutic targets. Funded by: Cancer Council of Tasmania - Grant-Small ($14,778); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Biomarkers to improve outcomes in prostate cancer (BIOPC)
    1 Jan 2021 - 31 Dec 2022
    People funded by this grant:
    • FitzGerald L,
    • Townley J,
    • Marthick J
    Project Total: $30,338; We propose to continue growing our clinical and biospecimens prostate cancer resource. This project aims to collect biological samples from Tasmanian men participating in the Prostate Cancer Outcomes Registry, Tasmania. This valuable clinical and genomic resource will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies. Funded by: Masonic Medical Research Foundation Limited ($30,338); University of Tasmania.
  • GRANT
    DNA Damage Repair Gene Variants in Clinically Significant Prostate Cancer
    1 Jan 2021 - 31 Dec 2021
    People funded by this grant:
    • Dickinson J,
    • FitzGerald L
    Project Total: $9,608; Genetic study to identify key mutations underpinning aggressive PrCa. Funded by: Cancer Council of Tasmania - Grant-Small ($9,608); University of Tasmania.
  • GRANT
    Real-world outcomes and toxicities for patients with non-small cell lung cancer receiving immunotherapy
    1 Jan 2021 - 31 Jul 2022
    People funded by this grant:
    • Roydhouse J,
    • Tay R,
    • Nott L,
    • Black A,
    • Grundy R
    Project Total: $4,375; The project seeks to develop a database of adverse events and outcomes for patients with non-small cell lung cancer who received PD-1/PD-L1 immunotherapy drugs in Southern Tasmania. As these drugs are increasingly in use, understanding their real-world impact, particularly for patients who would otherwise be trial-ineligible, is important. The goal of this project is to evaluate the incidence and severity of adverse events and important outcomes (survival, disease progression), and compare this based on key patient characteristics that affect trial eligibility (e.g. brain metastases, performance status). This will provide clinically relevant information about the patient experience on these therapies. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($4,375); University of Tasmania.
  • GRANT
    Utilising large Tasmanian families to determine the impact of rare genetic variation on prostate cancer.
    1 Jan 2021 - 30 Jun 2024
    People funded by this grant:
    • FitzGerald L,
    • Dickinson J,
    • Skala M,
    • Donovan S,
    • Redwig F
    Project Total: $349,920; This project aims to identify rare genetic changes that increase the chance of developing prostate cancer. To do this, we will apply cutting-edge technologies to a large Tasmanian familial prostate cancer resource comprising both germline (e.g. blood) and tumour samples. Funded by: Royal Hobart Hospital Research Foundation - Grant - Williams Oncology ($349,920); University of Tasmania.
  • GRANT
    A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania
    1 Jan 2020 - 31 Oct 2022
    People funded by this grant:
    • FitzGerald L,
    • Dickinson J,
    • Jones M,
    • Donovan S,
    • Murdolo V
    Project Total: $22,664; We propose to continue growing our clinical and biospecimens prostate cancer resource. This project aims to collect biological samples from Tasmanian men participating in the Prostate Cancer Outcomes Registry, Tasmania. This valuable clinical and genomic resource will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($22,664); University of Tasmania.
  • GRANT
    Gaining new insights into metastatic bone tumours
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Dickinson J,
    • Holloway A,
    • Nott L,
    • Liu G-S,
    • FitzGerald L
    Project Total: $24,925; Molecular analysis of prostate cancer tumour specimen to identify new molecular targets for therapy. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,925); University of Tasmania.